teriflunomide / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 14 Diseases   33 Trials   33 Trials   2608 News 


«12345678910111213...3132»
  • ||||||||||  Tysabri (natalizumab) / Biogen, Royalty, Ocrevus (ocrelizumab) / Roche
    Journal:  Multiple Sclerosis and Clostridium perfringens Epsilon Toxin: Is There a Relationship? (Pubmed Central) -  Jul 27, 2024   
    No significant differences in the quantity, diversity, and the relative abundance of fecal microbiota were observed in the gut microbiota of MS patients receiving various DMDs, including teriflunomide, natalizumab, ocrelizumab, and fingolimod, or no therapy. The present study did not provide evidence supporting the hypothesis of a causal relationship between Clostridium perfringens epsilon toxin and multiple sclerosis.
  • ||||||||||  Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Teriflunomide in Vitro or Leflunomide in Vivo Treatment Increases the Efficacy of Lurbinectedin in SCLC (30A) -  Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1106;    
    Conclusions : Collectively, our data suggest combinations of Lurbinectedin with Teriflunomide or Leflunomide are a potential therapeutic approach to suppress SCLC progression. These novel results pave the way for clinical trials in the future to validate these treatment strategies in patients with SCLC.
  • ||||||||||  Ocrevus (ocrelizumab) / Roche
    Journal:  Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation. (Pubmed Central) -  Jul 18, 2024   
    Therapy with ocrelizumab, teriflunomide or dimethyl fumarate reduced EBV-specific, but not CMV-specific MHC-I-restricted TRB sequence matches. Together, this data suggests that the aberrant MHC-I-restricted T-cell response directed against EBV is specific to MS with regard to NMO, MOGAD and Susac's Syndrome and that it is specifically modified by MS treatments interfering with EBV host cells or activated lymphocytes.
  • ||||||||||  teriflunomide / Generic mfg.
    Clinical, Journal, Real-world evidence, Real-world:  TAURUS-MS II: real-world use of teriflunomide in Germany and changes in treatment patterns over time. (Pubmed Central) -  May 29, 2024   
    Among the latter, previous DMTs were interferon (21%), glatiramer acetate (11%), and dimethyl fumarate (9%), and reasons for discontinuation were adverse events (AEs; 55%) and insufficient efficacy (16%)...Tolerability was comparable to previous trials. Bundesinstitut f
  • ||||||||||  evobrutinib (M2951) / EMD Serono, tolebrutinib (SAR442168) / Sanofi, fenebrutinib (GDC-0853) / Roche
    Journal:  Bruton tyrosine kinase inhibitors in multiple sclerosis: evidence and expectations. (Pubmed Central) -  Apr 29, 2024   
    Inhibition of BTK has emerged as a promising therapeutic approach to target the CNS-compartmentalized inflammation. Results from phase 3 clinical trials will shed light on differences in efficacy and safety of BTK inhibitors and its potential role in the future MS landscape.
  • ||||||||||  evobrutinib (M2951) / EMD Serono
    Trial completion date, Trial termination:  Study of Evobrutinib in Participants With RMS (evolutionRMS 2) (clinicaltrials.gov) -  Apr 29, 2024   
    P3,  N=1124, Terminated, 
    Results from phase 3 clinical trials will shed light on differences in efficacy and safety of BTK inhibitors and its potential role in the future MS landscape. Trial completion date: Jun 2026 --> Mar 2024 | Active, not recruiting --> Terminated; Results from the EVOLUTION clinical trials showed evobrutinib did not meet its primary endpoint of annualized relapse rate for up to 156 weeks compared to oral teriflunomide in both studies.
  • ||||||||||  evobrutinib (M2951) / EMD Serono
    Trial completion date, Trial termination:  EVOLUTION RMS1: Study of Evobrutinib in Participants With RMS (evolutionRMS 1) (clinicaltrials.gov) -  Apr 28, 2024   
    P3,  N=1124, Terminated, 
    Trial completion date: Jun 2026 --> Mar 2024 | Active, not recruiting --> Terminated; Results from the EVOLUTION clinical trials showed evobrutinib did not meet its primary endpoint of annualized relapse rate for up to 156 weeks compared to oral teriflunomide in both studies. Trial completion date: Jun 2026 --> Mar 2024 | Active, not recruiting --> Terminated; Results from the EVOLUTION clinical trials showed evobrutinib did not meet its primary endpoint of annualized relapse rate for up to 156 weeks compared to oral teriflunomide in both studies.
  • ||||||||||  teriflunomide / Generic mfg.
    Preclinical, Journal:  Antidepressant effect of teriflunomide via oligodendrocyte protection in a mouse model. (Pubmed Central) -  Apr 24, 2024   
    Additionally, TF treatment facilitated a reduction in the levels of apoptosis-related proteins while simultaneously augmenting the levels of Bcl2. Our findings indicate that TF administration effectively mitigates CORT-induced depression-like behaviors and reverses damage to oligodendrocytes and neurons in the hippocampus, suggesting TF as a promising candidate for depression.
  • ||||||||||  teriflunomide / Generic mfg.
    Journal:  The effect of multiple sclerosis therapy on gut microbiota dysbiosis: a longitudinal prospective study. (Pubmed Central) -  Apr 19, 2024   
    Among the PwMS, 20 were prescribed a disease-modifying therapy (DMT), either interferon beta1a or teriflunomide, while 19 received a combination of classical DMT and an immunoglobulin Y (IgY) supplement...Gut microbiota diversity in PwMS is not significantly different to HC.However, specific taxonomic changes indicate the presence of a dysbiosis state. The use of DMTs and immunoglobulin Y supplements may contribute to alterations in microbial composition, potentially leading to the restoration of a healthier microbiome.
  • ||||||||||  Promoting generic multiple sclerosis drug utilization and drug cost savings with a managed care pharmacist outreach program () -  Apr 9, 2024 - Abstract #AMCP2024AMCP_113;    
    An automated analytic rule process using claims data and providing MCP with actionable information successfully converted 16% of MS brand to generic thera- py cases, resulting in $9 million validated savings, with an additional $11 million savings potential among in-progress cases. Using a web application to facilitate MCP outreach can aid in transitioning to generic therapy, reducing total MS drug spend and member cost.
  • ||||||||||  Journal:  Prediction of disease activity and treatment failure in relapsing-remitting MS patients initiating daily oral DMTs. (Pubmed Central) -  Mar 29, 2024   
    Notably, 218 patients (62.4% females) initiating dimethyl fumarate, teriflunomide, and fingolimod were included...RS, mRS, and MAGNIMS 0 categories showed significantly lower EDA and treatment failure than the remainder. Scoring systems present different predictive abilities for disease activity parameters at 36?months in MS patients initiating daily oral therapies, warranting further adjustments (i.e. introduction of fluid biomarkers) to depict disease activity status fully.
  • ||||||||||  Auxora (zegocractin) / CalciMedica
    Journal:  Vulnerability of Store-Operated Calcium Entry to Inhibitors and Microenvironment in Cells of Different Breast Cancer Subtypes. (Pubmed Central) -  Mar 28, 2024   
    We have observed that the SOCE inhibitors Leflunomide and Teriflunomide suppress SOCE in the triple-negative BC cell line MDA-MB-231, but not in the luminal A BC cell line MCF-7...In addition, the oxygen scavenger sodium dithionide also affects SOCE, stimulating it in MDA-MB-231 cells but inhibiting in MCF-7 cells. Overall, our data highlight the importance of considering the different sensitivities of various BC cell types to inhibitors and to microenvironmental factors such as hypoxia and acidification when developing targeted drugs.
  • ||||||||||  teriflunomide / Generic mfg.
    Journal:  Brain-Derived Neurotrophic Factor in Multiple Sclerosis Disability: A Prospective Study. (Pubmed Central) -  Mar 28, 2024   
    We analysed the serum levels of BDNF and MS specific disability tests (Expanded Disability Status Scale, timed 25-foot walk test, nine-hole peg test), at baseline (V0) and after one year of interferon beta1a or teriflunomide treatment (V1)...In our cohort, the PwMS had higher BDNF levels compared to the HCs after one year of treatment. BDNF was not related to clinical or paraclinical disease severity signs.
  • ||||||||||  Retrospective data, Journal:  Incidence of type 2 diabetes, cardiovascular disease and chronic kidney disease in patients with multiple sclerosis initiating disease-modifying therapies: Retrospective cohort study using a frequentist model averaging statistical framework. (Pubmed Central) -  Mar 26, 2024   
    This retrospective cohort study used administrative claims data to derive four cohorts of adults with multiple sclerosis initiating dimethyl fumarate, teriflunomide, glatiramer acetate or fingolimod between January 2013 and December 2018...This study effectively demonstrated the use of an innovative statistical methodology to test a clinical hypothesis using real-world data to perform early target validation for drug discovery. Although there was a trend among patients treated with dimethyl fumarate towards a decreased incidence of type 2 diabetes, cardiovascular disease and chronic kidney disease relative to other disease-modifying therapies-which was statistically significant for the comparison with teriflunomide-this study did not definitively support the hypothesis that Nrf2 activation provided additional metabolic disease benefit in patients with multiple sclerosis.
  • ||||||||||  Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Journal, HEOR, Real-world evidence, Real-world:  Shifting from the treat-to-target to the early highly effective treatment approach in patients with multiple sclerosis - real-world evidence from Germany. (Pubmed Central) -  Mar 25, 2024   
    Medication classification adhered to the German Society of Neurology guidelines and designated fumarates, glatiramer acetate, teriflunomide and interferons as low-efficacy category 1 medications; cladribine and S1P-modulators as medium-efficacy category 2 medications; and alemtuzumab, natalizumab, ocrelizumab, ofatumumab and rituximab (off-label) as high-efficacy category 3 medications...While most individuals started their treatment according to the treat-to-target approach and remained on their initially prescribed medication category, there has been a steadily increasing shift towards the EHT approach since 2020. These insights demonstrate that, while not officially recommended by German guidelines, MS providers increasingly adopt the EHT approach.
  • ||||||||||  dimethyl fumarate / Generic mfg., teriflunomide / Generic mfg.
    Review, Journal:  Radiologically isolated syndromes: to treat or not to treat? (Pubmed Central) -  Mar 19, 2024   
    Recent randomized controlled trials conducted in individuals with RIS have shown that dimethyl fumarate and teriflunomide significantly reduce the occurrence of clinical events in this population...However, several aspects should be taken into account before treating individuals with RIS in the real-world clinical setting, including an accurate identification of individuals with RIS to avoid misdiagnosis, a precise stratification of their risk of experiencing a first clinical event and further data supporting favorable balance between benefits and risks, even in the long term. This commentary provides an overview of the latest updates in RIS diagnosis, prognosis, and emerging treatment evidence.
  • ||||||||||  teriflunomide / Generic mfg.
    Journal:  Serum teriflunomide concentrations in routine multiple sclerosis therapy: A cross-sectional pilot study. (Pubmed Central) -  Mar 18, 2024   
    Although all patients were treated with the same dose, up to a 10-fold difference in total and free teriflunomide serum concentrations, and up to a 5-fold difference in steady-state trough concentrations were observed. This vast interindividual variability can potentially lead to toxicity or, conversely, to suboptimal therapeutic concentrations of teriflunomide, with the risk of further worsening of multiple sclerosis compensation.
  • ||||||||||  teriflunomide / Generic mfg.
    Enrollment closed, Trial completion date, Trial primary completion date:  ULTIMS: Ultra-high-field Brain MRI in Multiple Sclerosis (clinicaltrials.gov) -  Mar 13, 2024   
    P=N/A,  N=10, Active, not recruiting, 
    This vast interindividual variability can potentially lead to toxicity or, conversely, to suboptimal therapeutic concentrations of teriflunomide, with the risk of further worsening of multiple sclerosis compensation. Recruiting --> Active, not recruiting | Trial completion date: Mar 2024 --> Aug 2024 | Trial primary completion date: Mar 2024 --> Jul 2024
  • ||||||||||  Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
    Prognostic Value of On-treatment Serum Neurofilament Light Chain for New or Enlarging T2 Lesions in People with Relapsing Multiple Sclerosis: Pooled Analysis of the ASCLEPIOS I/II Trials (Colorado Convention Center | 603) -  Mar 8, 2024 - Abstract #AAN2024AAN_4645;    
    Furthermore, the lack of a discernible pattern in the effects of DMTs on blood immune cells suggests that multiple immune cells can independently modulate the disease. Background:In the Phase 3 ASCLEPIOS I/II trials (ofatumumab versus teriflunomide in pwRMS), baseline sNfL levels were prognostic for on-study lesion formation and brain volume loss in the overall population and in recently diagnosed treatment-naive participants...On-treatment sNfL levels at 3 and 12 months continue to be prognostic for future lesion formation and support the use of sNfL as a prognostic biomarker for MS disease activity in pwRMS on disease-modifying therapy.